Epithelial Ovarian Cancer

TL;DR: This study reveals that TAZ promotes ferroptosis in ovarian cancers by regulating ANGPTL4 and NOX, offering a novel therapeutic potential for ovarian tumors with TAZ activation.

TL;DR: PARPis are not recommended for use in combination with chemotherapy, other targeted agents, or immune-oncology agents in the recurrent setting outside the context of a clinical trial, and data to support reuse of PARPis in any setting are needed.

TL;DR: Several mechanisms by which physical exercise might cause changes in gut microbiota are proposed, including the promotion of an anti-inflammatory state, reinforcement of the neuromuscular function, and activation of the hypothalamic-pituitary-adrenal axis.

TL;DR: The principle mechanisms of VEGF-mediated immunosuppression studied in preclinical models or as part of translational clinical studies are discussed and how these concepts and approaches can be further incorporated into clinical practice to improve immunotherapy outcomes for patients with cancer are discussed.

TL;DR: The hypothesis that patients with platinum-sensitive recurrent serous ovarian cancer with a BRCA mutation have the greatest likelihood of benefiting from olaparib treatment is supported.

TL;DR: GC plus BV followed by BV until progression resulted in a statistically significant improvement in PFS compared with GC plus PL in platinum-sensitive ROC, and the primary end point was progression-free survival by RECIST.

TL;DR: The FIGO Committee on Gynecologic Oncology feels that it is time to revise this classification to improve utility and reproducibility.

TL;DR: In women with stage III or IV ovarian cancer, survival with primary chemotherapy is non-inferior to primary surgery, and giving primary chemotherapy before surgery is an acceptable standard of care for women with advanced ovarian cancer.